Feasibility and safety of SGLT2 inhibition by empagliflozin for the preservation of pancreas function in recent-onset type 1 diabetes.
Phase of Trial: Phase II
Latest Information Update: 13 Feb 2018
At a glance
- Drugs Empagliflozin (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- 12 Feb 2018 Planned End Date changed from 30 Nov 2018 to 31 Mar 2019.
- 10 Mar 2017 Status changed from not yet recruiting to recruiting.
- 06 Jan 2017 New trial record